An observational study published in the Lancet alerted to the risks linked to the treatment promoted by Professor Raoult and called for further clinical trials.
A new study has cast doubt on the value of hydroxychloroquine for treating patients with Covid-19. This work, published this Friday in the prestigious review The Lancet, alone will not be enough to close the debate on this molecule. But it constitutes an alert to be taken very seriously about the interest and the potential risks of this treatment.
Its authors, Swiss and American scientists (from Harvard University in particular), delved into the hospital registers of 671 health establishments on six continents. They looked for data relating to patients hospitalized for a Covid between December 20, 2019 and April 14, 2020, and examined the fate of patients who received treatment with chloroquine, hydroxychloroquine, or l within 48 hours of their admission. one of these two molecules combined with an antibiotic.
Article reserved for subscribers
To continue reading, subscribe and take advantage of our offer
1 € the 1st month
I subscribe now
Included in the Digital and Audio subscription
- Audio magazine and augmented digital magazine
- L’Express Masterclass
- Unlimited access to articles without ads
- Access to all newsletters
Already subscribed? To log in